Stock Analysis of Gelesis Holdings Inc (GLS) - Birds Eye View

1W   2W   1M   3M   1Y   2Y   5Y   
Overview
Code GLS
Close 0.0120
Change -0.0180 / 60.00 %
Volume 1567.50 K
Vol Change 19794.00 / 1.28 %
IndustryBiotechnology
SectorHealthcare
AIO Strength Index
Technical StrengthStrong Bearish
Growth Index Poor Growth Stock
Value Index Very Low Value Stock
Profitability Index Poor Profitability Stock
Stability Index Poor Stability Stock


Fundamental View of Gelesis Holdings Inc
PE (TTM)

0.0171

Excellent
Price / Book

-0.163

Very Poor
Price / Sales

0.365

Excellent
Piotroski F Score

4.0

Indecisive
Market Cap

879991

Enterprise Value

26275.28 K

ROA (TTM)

78.34

Excellent
ROE (TTM)

0

Poor
Net Margin (TTM)

2143.20

Excellent
Revenue

130.37 %

25767.00 K
Net Profit

1.84 %

-95062.00 K
Debt to Equity

-1013.84

Very Poor
Altman Z Score

-3052.97

Very Poor
Quick Ratio

0.130

Poor
Cash Ratio

0.080

Poor


Highs/Lows of Gelesis Holdings Inc
PeriodOld priceStock ReturnS&P 500 ReturnsHighLowHigh DateLow Date
One Week0.158 92.41 % 1.54 % 0.16220.01210-Apr-2313-Apr-23
Two Week0.171 92.98 % 3.42 % 0.2020.01204-Apr-2313-Apr-23
One Month0.2277 94.73 % 5.60 % 0.2870.01220-Mar-2313-Apr-23
Three Month0.355 96.62 % 5.95 % 0.410.01225-Jan-2313-Apr-23
Six Months0.958 98.75 % 17.48 % 1.040.01214-Oct-2213-Apr-23
One year4.94 99.76 % 27.52 % 5.670.01202-May-2213-Apr-23
Two year9.9 99.88 % 29.70 % 12.230.01210-Jan-2213-Apr-23


Technical View of Gelesis Holdings Inc
RSI

25.91

Mild Bullish
MACD

-0.0460

Mild Bearish
ADX

15.17

Bearish
Super Trend

0.142

Mild Bearish
Williams %R

-100.00

Mild Bullish
CCI

-246.52

Mild Bullish


EMA 5

0.064

Strong Bearish
EMA 15

0.127

Strong Bearish
EMA 50

0.215

Strong Bearish
EMA 100

0.397

Strong Bearish
SMA 100

0.286

Strong Bearish
SMA 200

0.691

Strong Bearish
SMA 5 / 20

0.077 / 0.149

Strong Bearish
SMA 15 / 50

0.143 / 0.224

Strong Bearish
SMA 50 / 200

0.224 / 0.691

Mild Bearish




Charts of Gelesis Holdings Inc


Returns of Gelesis Holdings Inc with Peers
Period / StockGLSCMRAHSTOACOR
1 Week-92.41%37.74%5.00%-60.65%
1 Mth-94.73%-28.78%-58.00%-94.49%
3 Mth-96.62%-16.57%-37.31%-95.96%
6mth-98.75%-31.29%-38.24%-93.85%
1 Year-99.76%-95.13%-72.73%-93.99%
2 Year-99.88%-99.72%-94.57%-98.01%
5 Years---99.88%-99.96%
charts-
View All Together in Chart      Inline           Tile

Compare Fundamentals of Gelesis Holdings Inc with Peers
Ratio / StockGLSCMRAHSTOACOR
PE0.0171-0.0001-52.30-0.0017
P/B-0.163-0.001263.95-0.0346
ROA78.34-379.05-83.91-170.31
ROE00-111.370
Debt To Equity-1013.8400-0.0101
Revenue25767.00 K
130.37 % 		1000.40 K
58.02 % 		19000.00
99.50 % 		111118 K
6.28 %
Net Income-95062.00 K
1.84 % 		-9009.24 K
49.96 % 		-12377.00 K
11.41 % 		-15951.00 K
75.80 %


Technicals of Gelesis Holdings Inc with Peers
Technical / StockGLSCMRAHSTOACOR-
ADX15.1720.7631.9739.16
CMF-0.1940.3070.291-0.438
MFI33.162.4149.110.925
RSI25.9145.5939.2917.04
MACD Abv SignalFalseFalseFalseFalse
Price Above 50 MAFalseFalseFalseFalse-
Price Above 200 MAFalseFalseFalseFalse-


About : Gelesis Holdings Inc

Address : 501 Boylston Street, Boston, MA, United States, 02116
Tel : 617 456 4718
URL : https://www.gelesis.com
Code : GLS, ISIN : US36850R2040, Exchange : NYSE, Country : USA
Fiscal Year End : December
IPO date : 13_Jan_2022
Employee Count : 93

Gelesis Holdings, Inc., a commercial stage biotherapeutics company, developing a biomimicry to treat the genesis of obesity and GI-related chronic diseases. It also offers PLENITY, an orally administered, non-stimulant, and non-systemic aid for weight management. In addition, the company develops GS200 for weight loss in prediabetes and type 2 diabetes; and GS500 for functional constipation. Further, it develops pre-clinical product GS300 for non-alcoholic fatty liver disease/non-alcoholic steatohepatitis. Gelesis Holdings, Inc. was incorporated in 2006 and is headquartered in Boston, Massachusetts.


Note : All Data Generated at the End of Trading Hours (EOD Data)